Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| JAZZ | 8-K | bullish | 6/10 | Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfro | Aug 10, 2026 |
| REPL | 424B5 | bearish | 7/10 | Replimune Group is conducting a $150 million underwritten public offering of 9,701,490 shares of common stock and pre-fu | Aug 10, 2026 |
| ABCL | 8-K | bullish | 7/10 | AbCellera announced positive top-line Phase 2 results for ABCL635, an NK3R antagonist antibody for moderate-to-severe va | Aug 10, 2026 |
| REPL | 8-K | bearish | 6/10 | Replimune Group priced a $150M underwritten offering of 9.7M common shares at $12.06/share and 2.7M pre-funded warrants | Aug 10, 2026 |
| SLN | 8-K | bullish | 7/10 | Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polycythemia vera (PV). T | Aug 10, 2026 |
| OCS | 6-K | neutral | 5/10 | Oculis Holding AG (OCS) filed a Form 6-K with the SEC. The filing contains routine corporate updates and standard regula | Aug 10, 2026 |
| TELO | 8-K | neutral | 4/10 | Telomir Pharmaceuticals announced a peer-reviewed publication of preclinical data for Telomir-Zn in triple-negative brea | Aug 10, 2026 |
| CLNN | 8-K | bullish | 7/10 | Clene Inc. announced new biomarker analyses linking CNM-Au8 treatment to reduced neurofilament light chain (NfL) levels | Aug 10, 2026 |
| FULC | 8-K | neutral | 2/10 | Fulcrum Therapeutics VP of Finance and principal accounting officer Greg Tourangeau mutually agreed to depart, effective | Aug 10, 2026 |
| TBPH | 8-K | bullish | 7/10 | Theravance Biopharma reported Q2 2026 earnings with no analyst consensus provided for the current period. The filing is | Aug 10, 2026 |
| ASBP | 8-K | bullish | 7/10 | Aspire Biopharma completed its acquisition of Dura Driver Control Systems (DCS) for approximately $30M in cash, funded b | Aug 10, 2026 |
| AIM | 8-K | bearish | 5/10 | AIM ImmunoTech reported Q2 2026 results with a net loss of $(3.8M) or $(0.43) per share, significantly missing the conse | Aug 10, 2026 |
| HRTX | 8-K | bearish | 7/10 | Heron Therapeutics withdrew full-year 2026 guidance and announced a strategic alternatives review, citing a June 2026 co | Aug 10, 2026 |
| COGT | 8-K | neutral | 5/10 | Cogent Biosciences reported a wider net loss of $96.4M for Q2 2026 vs. $73.5M a year ago, reflecting scaling R&D and com | Aug 10, 2026 |
| KPTI | PRESS-RELEASE | neutral | 1/10 | Karyopharm Therapeutics Inc. announced it will report its Q2 2026 results on August 13, 2026. | Aug 10, 2026 |
| AXSM | PRESS-RELEASE | mixed | 6/10 | Axsome reported Q2 2026 net product revenue of $218.4M (+46% YoY), beating the $221.8M consensus, but GAAP EPS of -$1.26 | Aug 10, 2026 |
| AXSM | 8-K | neutral | 6/10 | Axsome Therapeutics reported Q2 2026 total net product revenue of $218.4M (+46% YoY), driven by AUVELITY ($180.3M, +51% | Aug 10, 2026 |
| JBIO | 8-K | bullish | 7/10 | Jade Biosciences reported Q2 2026 results with net loss of -$0.76 per share (vs -$0.86 YoY), a pre-revenue clinical-stag | Aug 10, 2026 |
| MLTX | 8-K | bullish | 7/10 | MoonLake announced positive topline Phase 3 IZAR-1 results for sonelokimab in psoriatic arthritis, meeting all clinical | Aug 10, 2026 |
| TNXP | 8-K | bullish | 6/10 | Tonix Pharmaceuticals reported Q2 2026 net product revenue of $13.5M, up 578% YoY from $2.0M, driven by $11.0M in TONMYA | Aug 10, 2026 |
| VERU | PRESS-RELEASE | bullish | 7/10 | Veru reported fiscal Q3 2026 results with a net loss of -$0.30 per share, beating the -$0.32 consensus by 6.3%. The key | Aug 10, 2026 |
| TNXP | PRESS-RELEASE | mixed | 6/10 | Tonix Pharmaceuticals reported Q2 2026 net product revenue of $13.5M, up from $2.0M a year ago, driven by $11.0M in TONM | Aug 10, 2026 |
| JBIO | PRESS-RELEASE | bullish | 7/10 | Jade Biosciences reported Q2 2026 financial results with a net loss of $55.8M, wider than the $32.1M loss in Q2 2025, dr | Aug 10, 2026 |
| APGE | 8-K | bullish | 8/10 | Apogee reported Q2 2026 financial results amid a transformational period: positive Phase 2 APEX Part B data for lead ass | Aug 10, 2026 |
| MLTX | PRESS-RELEASE | bullish | 7/10 | MoonLake reported positive Phase 3 IZAR-1 topline results for sonelokimab in psoriatic arthritis, meeting all primary an | Aug 10, 2026 |
| SLN | 8-K | neutral | 5/10 | Silence Therapeutics reported Q2 2026 net loss of $12.3M ($0.09 per share), narrower than the $27.4M loss in Q2 2025 and | Aug 10, 2026 |
| APGE | PRESS-RELEASE | bullish | 8/10 | Apogee Therapeutics reported Q2 2026 results but the quarter's significance is completely overshadowed by AbbVie's pendi | Aug 10, 2026 |
| ORKA | PRESS-RELEASE | bullish | 7/10 | Oruka Therapeutics reported Q2 2026 results in line with pre-revenue expectations: EPS of -$0.55 (consensus -$0.50) was | Aug 10, 2026 |
| ORKA | 8-K | neutral | 5/10 | The company highlighted key upcoming catalysts including Week 28 data from EVERLAST-A and Week 16 data from EVERLAST-B, | Aug 10, 2026 |
| GRFS | PRESS-RELEASE | neutral | 4/10 | Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating P | Aug 10, 2026 |